Apogee Therapeutics (APGE) Price & Analysis

Compare

348 Followers

APGE Stock Chart & Stats

$69.98

-$0.82(-1.65%)

At close: Jan 08 4:00 PM EST

$69.98

-$0.82(-1.65%)

Day’s Range― - ―

52-Week Range$26.20 - $84.56

Previous CloseN/A

Volume109.80K

Average Volume (3M)961.52K

Market Cap

$4.83B

Enterprise Value$3.49B

Total Cash (Recent Filing)$527.29M

Total Debt (Recent Filing)$9.85M

Price to Earnings (P/E)―

Beta1.17

Next Earnings

Mar 10, 2026

EPS Estimate

-1.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.11

Shares Outstanding54,833,588

10 Day Avg. Volume985,257

30 Day Avg. Volume961,516

Financial Highlights & Ratios

PEG Ratio-0.14

Price to Book (P/B)3.49

Price to Sales (P/S)0.00

P/FCF Ratio-14.51

Enterprise Value/Market Cap0.72

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-8.74K

Enterprise Value/Ebitda-12.66

Forecast

1Y Price Target

$105.67

Price Target Upside51.00% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering15

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy And DosingPhase 1b data showed strong, sustained reductions in a key asthma biomarker and encouraging lung function signals after a single injection, supporting the potential for infrequent maintenance dosing and broader use across asthma and atopic dermatitis.

Competitive PositioningA competitor’s lower efficacy readout and an isolated safety event may confine that drug to later‑line patients, reducing direct competitive pressure and preserving market opportunity for zumilokibart.

Upcoming Clinical MilestonesMultiple forthcoming clinical readouts, including maintenance and induction data plus head‑to‑head comparisons versus an established therapy, present catalysts that could materially boost valuation if results confirm current signals.

Bears Say

Data Robustness And Trial SizeThe small size of the phase 1b dataset and imbalances in background asthma medications limit confidence in the findings and hinder the ability to draw definitive conclusions on efficacy and safety.

Safety And Potential Class RiskA reported cancer case in a trial of a T‑cell–targeting therapy raises concern that similar mechanisms might pose a class safety risk and attract heightened regulatory scrutiny.

Uncertain Translation Of Biomarkers To Clinical BenefitObserved biomarker improvements leave uncertainty about the magnitude of real symptom improvement, so larger studies are required to confirm that biological effects translate into meaningful patient benefit.

Apogee Therapeutics News

Apogee selloff on Sanofi data brings opportunity, says UBS

UBS analyst Michael Yee says Apogee Therapeutics (APGE) sold off Friday following Sanofi’s (SNY) positive Phase III OX40L...

6d ago

SNY

APGE

Apogee Therapeutics selloff on Sanofi data overdone, says Citi

Citi says Friday’s selloff in shares of Apogee Therapeutics (APGE) following Sanofi’s (SNY) Phase 3 amlitelimab data is...

6d ago

SNY

APGE

Apogee Therapeutics falls -13.0%

Apogee Therapeutics (APGE) is down -13.0%, or -$10.42 to $69.44. Published first on TheFly – the ultimate source...

8d ago

APGE

Mizuho biotech analysts hold an analyst/industry conference call

Biotech Analysts, along with Dr. Brian Lester, a leading dermatologist, participates in an Analyst/Industry conference call entitled, “Recent...

8d ago

APGE

CRVS

Apogee Therapeutics downgraded to Sector Perform from Outperform at RBC Capital

RBC Capital downgraded Apogee Therapeutics (APGE) to Sector Perform from Outperform with a price target of $83, up...

9d ago

APGE

Wayfair upgraded, Instacart initiated: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

24d ago

HSY

Apogee Therapeutics price target raised to $116 from $109 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Apogee Therapeutics (APGE) to $116 from $109 and keeps a Buy...

24d ago

APGE

Aligos Therapeutics initiated with a Buy at UBS

UBS analyst Michael Yee initiated coverage of Aligos Therapeutics (ALGS) with a Buy rating and $20 price target...

24d ago

IVA

KOD

Apogee Therapeutics initiated with a Peer Perform at Wolfe Research

Wolfe Research initiated coverage of Apogee Therapeutics (APGE) with a Peer Perform rating and no price target While...

24d ago

APGE

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

There’s plenty of stock market stories traders will want to keep tabs on in the TipRanks daily wrap-up for Tuesday. ...

25d ago

AMD

Apogee Therapeutics price target raised to $84 from $81 at BofA

BofA analyst Tim Anderson raised the firm’s price target on Apogee Therapeutics (APGE) to $84 from $81 and...

25d ago

APGE

Apogee Therapeutics Stock (APGE) Plunges despite ‘Positive’ Asthma Drug Trial

Shares in biotech firm Apogee Therapeutics ($APGE) sank about 5% early Tuesday despite reporting “positive” results from its...

25d ago

JNJ

APGE

Apogee Therapeutics: Upgraded Outlook on Zumilokibart’s Superior Asthma Data, Dual-Label Potential, and Strengthened Buy Thesis

Apogee Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Julian Harrison from...

25d ago

APGE

Apogee Therapeutics: Differentiated IL-13 Strategy, Durable Efficacy, and 2026 Catalysts Underpin Reaffirmed Buy Rating

Stifel Nicolaus analyst Alex Thompson CFA has maintained their bullish stance on APGE stock, giving a Buy rating...

25d ago

APGE

APGE FAQ

What was Apogee Therapeutics’s price range in the past 12 months?

Apogee Therapeutics lowest stock price was $26.20 and its highest was $84.56 in the past 12 months.

What is Apogee Therapeutics’s market cap?

Apogee Therapeutics’s market cap is $4.83B.

When is Apogee Therapeutics’s upcoming earnings report date?

Apogee Therapeutics’s upcoming earnings report date is Mar 10, 2026 which is in 38 days.

How were Apogee Therapeutics’s earnings last quarter?

Apogee Therapeutics released its earnings results on Nov 10, 2025. The company reported -$1.11 earnings per share for the quarter, beating the consensus estimate of -$1.175 by $0.065.

Is Apogee Therapeutics overvalued?

According to Wall Street analysts Apogee Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Apogee Therapeutics pay dividends?

Apogee Therapeutics does not currently pay dividends.

What is Apogee Therapeutics’s EPS estimate?

Apogee Therapeutics’s EPS estimate is -1.05.

How many shares outstanding does Apogee Therapeutics have?

Apogee Therapeutics has 54,833,588 shares outstanding.

What happened to Apogee Therapeutics’s price movement after its last earnings report?

Apogee Therapeutics reported an EPS of -$1.11 in its last earnings report, beating expectations of -$1.175. Following the earnings report the stock price went up 3.765%.

Which hedge fund is a major shareholder of Apogee Therapeutics?

Currently, no hedge funds are holding shares in APGE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Apogee Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-38.41%

Trailing 12-Months

Asset Growth

-19.34%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Apogee Therapeutics

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Apogee Therapeutics (APGE) Earnings & Revenues

Historic Earnings Reports

APGE Stock 12 Month Forecast

Average Price Target

$105.67

▲(51.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"$30","57":"$57","84":"$84","111":"$111","138":"$138"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":137,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$137.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$105.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$83.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,57,84,111,138],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.48,80.21230769230769,84.94461538461539,89.67692307692307,94.40923076923077,99.14153846153846,103.87384615384616,108.60615384615384,113.33846153846153,118.07076923076923,122.80307692307693,127.53538461538461,132.2676923076923,{"y":137,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.48,77.80230769230769,80.12461538461538,82.44692307692308,84.76923076923077,87.09153846153846,89.41384615384615,91.73615384615385,94.05846153846154,96.38076923076923,98.70307692307692,101.02538461538461,103.34769230769231,{"y":105.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,75.48,76.05846153846154,76.63692307692308,77.21538461538462,77.79384615384616,78.3723076923077,78.95076923076924,79.52923076923076,80.1076923076923,80.68615384615384,81.26461538461538,81.84307692307692,82.42153846153846,{"y":83,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.3,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.61,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.33,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.26,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.75,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.38,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.59,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.48,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >